Welcome to Paid Research Studies




  • Condition:   Adrenal Insufficiency
    Intervention:   Drug: Infacort
    Sponsors:   Diurnal Limited;   Simbec Research;   Emas Pharma Ltd.;   Voet Consulting;   Brush Clinical Research Ltd.;   Medical Matters International Ltd.
    Recruiting - verified June 2017

  • Condition:   Primary Aldosteronism
    Intervention:   Drug: Everolimus 0.75 mg
    Sponsor:   University Hospital, Basel, Switzerland
    Recruiting - verified May 2017

  • Conditions:   Primary Aldosteronism;   Primary Aldosteronism Due to Aldosterone Producing Adenoma;   Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
    Interventions:   Procedure: Adrenalectomy;   Drug: Mineralocorticoid Receptor Antagonists
    Sponsor:   Changi General Hospital
    Recruiting - verified May 2017

  • Conditions:   Osteoporosis in Cushing's Syndrome;   Osteoporosis in Post-menopausal Women
    Intervention:   Other: Osteodensitometry and pQCT
    Sponsors:   University Hospital, Clermont-Ferrand;   Unité de recherche GReD CNRS UMR6293 / Inserm
    Recruiting - verified May 2017

  • Condition:   Congenital Adrenal Hyperplasia
    Intervention:   Other: Collection of growth and bone maturation data
    Sponsor:   Hospices Civils de Lyon
    Recruiting - verified May 2017

  • Condition:   X-linked Adrenoleukodystrophy
    Intervention:   Drug: Sobetirome
    Sponsor:   NeuroVia, Inc.
    Not yet recruiting - verified June 2017

  • Conditions:   Hyperaldosteronism; Primary;   Hypertension Secondary
    Interventions:   Diagnostic Test: Aldosterone/renin ratio (ARR) testing;   Diagnostic Test: Confirmatory tests
    Sponsors:   Qifu Li;   Fu Wai Hospital, Beijing, China
    Recruiting - verified May 2017

  • Condition:   Adrenal Insufficiency
    Intervention:  
    Sponsors:   Chronic Obstructive Pulmonary Disease Trial Network, Denmark;   Rigshospitalet, Denmark
    Not yet recruiting - verified May 2017

  • Conditions:   Inflammatory Disorder;   Autoimmune
    Interventions:   Drug: Prednisone;   Other: Placebo Arm
    Sponsors:   University Hospital, Basel, Switzerland;   Kantonsspital Baselland Bruderholz
    Recruiting - verified June 2017

  • Condition:   Psoriasis
    Intervention:   Drug: DFD06
    Sponsor:   Promius Pharma, LLC
    Recruiting - verified June 2017

  • Conditions:   Adrenocortical Carcinoma;   Peritoneal Carcinomatosis
    Interventions:   Drug: Cisplatin;   Drug: Sodium thiosulfate;   Procedure: Cytoreductive surgery
    Sponsor:   Columbia University
    Not yet recruiting - verified April 2017

  • Conditions:   Primary Aldosteronism;   Hypertension;   Hypertension Secondary
    Intervention:  
    Sponsors:   Uppsala University;   Uppsala-Örebro Regional Research Council
    Recruiting - verified April 2017

  • Condition:   Spinal Anesthetics Causing Adverse Effects in Therapeutic Use
    Interventions:   Drug: Epinephrine;   Drug: Norepinephrine;   Drug: Phenylephrine
    Sponsor:   Cukurova University
    Not yet recruiting - verified May 2017

  • Conditions:   Pheochromocytoma;   Paraganglioma;   Inherited Cancer Syndrome;   Associated Conditions;   Kidney Neoplasms;   Bone Cancer;   Thyroid Neoplasms;   Other Cancer
    Intervention:   Genetic: Genetic screening
    Sponsor:   The University of Texas Health Science Center at San Antonio
    Recruiting - verified May 2017

  • Conditions:   Adrenal Insufficiency;   Adrenal Cancer
    Intervention:   Diagnostic Test: Cosyntropin stimulation test
    Sponsor:   Bnai Zion Medical Center
    Not yet recruiting - verified March 2017

  • Condition:   Iatrogenic Cushing's Disease
    Interventions:   Drug: AZD4017 and prednisolone;   Drug: Placebo Oral Tablet and prednisolone
    Sponsors:   University of Oxford;   AstraZeneca
    Not yet recruiting - verified April 2017

  • Condition:   Adrenal Insufficiency
    Intervention:   Diagnostic Test: low-dose cosyntropin stimulation test
    Sponsor:   Bnai Zion Medical Center
    Not yet recruiting - verified March 2017

  • Conditions:   Paraganglioma;   Gastrointestinal Stromal Tumors;   Carcinoma, Renal Cell;   Renal Neoplasms;   Pheochromocytoma
    Intervention:   Drug: SGI-110 (guadecitabine)
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting - verified April 13, 2017

  • Condition:   Endocrine Disease
    Interventions:   Other: Data Collection;   Behavioral: Follow Up
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified February 2017

  • Condition:   Adrenal Insufficiency
    Intervention:   Diagnostic Test: Synacthen test
    Sponsor:   Rigshospitalet, Denmark
    Recruiting - verified May 2017

  • Conditions:   Lung Transplant; Complications, Mechanical;   Lung Transplant; Complications;   Bleeding;   Hemoptysis
    Interventions:   Drug: Topical epinephrine;   Drug: Placebos
    Sponsor:   University of Maryland
    Not yet recruiting - verified May 2017

  • Condition:   Cushing Syndrome
    Interventions:   Drug: ATR-101;   Drug: Placebos
    Sponsor:   Millendo Therapeutics, Inc.
    Recruiting - verified March 2017

  • Conditions:   Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukaemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified February 2017

  • Conditions:   Pancreatitis;   Endoscopic Retrograde Cholangiopancreatography
    Interventions:   Drug: Papillary epinephrine spraying;   Drug: Papillary saline spraying;   Drug: Indomethacin
    Sponsor:   Fourth Military Medical University
    Recruiting - verified February 2017

  • Condition:   Adrenal Insufficiency
    Intervention:  
    Sponsor:   University of Chicago
    Recruiting - verified February 2017

  • Condition:   Cardiac Arrest
    Intervention:   Drug: Epinephrine
    Sponsor:   Haukeland University Hospital
    Not yet recruiting - verified February 2017

  • Condition:   Labor Pain
    Interventions:   Other: Continuous epidural infusion;   Other: Intermittent epidural bolus
    Sponsor:   University Hospital, Akershus
    Recruiting - verified March 2017

  • Condition:   Adrenoleukodystrophy
    Intervention:   Procedure: newborns testing for ALD
    Sponsor:   National Taiwan University Hospital
    Recruiting - verified January 2017

  • Condition:   Adrenal Insufficiency Neonatal
    Intervention:   Other: No pre-operative steroids
    Sponsor:   University of Alabama at Birmingham
    Recruiting - verified November 2016

  • Condition:   Adrenoleukodystrophy
    Intervention:  
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified November 2016

  • Condition:   Apparent Mineralocorticoid Excess
    Intervention:   Dietary Supplement: Liquorice
    Sponsor:   The Royal Wolverhampton Hospitals NHS Trust
    Not yet recruiting - verified October 2016

  • Condition:   Cushing's Syndrome
    Intervention:  
    Sponsor:   Corcept Therapeutics
    Recruiting - verified March 2017

  • Condition:   Pancreatitis, Acute
    Interventions:   Drug: Epinephrine;   Other: Sterile water;   Drug: Indomethacin Rectal Suppository
    Sponsor:   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    Recruiting - verified November 2016

  • Conditions:   Carpal Tunnel Syndrome;   Anesthesia
    Interventions:   Procedure: Intravenous regional anesthesia (Bier);   Procedure: Local anesthesia with adrenaline
    Sponsors:   Hospital Alvorada;   Federal University of São Paulo
    Not yet recruiting - verified April 2017

  • Conditions:   Primary Aldosteronism;   Hyperaldosteronism
    Intervention:   Procedure: adrenalectomy
    Sponsors:   Queen Mary University of London;   National Institute for Health Research, United Kingdom;   WBIC), Cambridge. University of Cambridge Addenbrookes Hospital, Cambridge CB2 2QQ;   Robertson Centre for Biostatistics University of Glasgow Glasgow G12 8QQ;   Barts and the London School of Medicine and Dentistry W Smithfield London - City of London EC1A 7BE
    Not yet recruiting - verified August 2016

  • Condition:   Plaque Psoriasis
    Intervention:   Drug: DSXS topical
    Sponsor:   Taro Pharmaceuticals USA
    Recruiting - verified May 2017

  • Condition:   Psoriasis
    Intervention:   Drug: DSXS Topical product
    Sponsor:   Taro Pharmaceuticals USA
    Recruiting - verified May 2017

  • Condition:   Scalp Psoriasis
    Intervention:   Drug: DSXS topical product
    Sponsor:   Taro Pharmaceuticals USA
    Recruiting - verified May 2017

  • Condition:   Atopic Dermatitis
    Intervention:   Drug: DSXS topical
    Sponsor:   Taro Pharmaceuticals USA
    Recruiting - verified May 2017

  • Condition:   Congenital Adrenal Hyperplasia
    Intervention:   Drug: Hydrocortisone
    Sponsor:   Diurnal Limited
    Recruiting - verified February 2017

  • Conditions:   Adrenal Cortex Carcinoma;   Adult Alveolar Soft Part Sarcoma;   Adult Clear Cell Sarcoma of Soft Parts;   Adult Hepatocellular Carcinoma;   Adult Rhabdomyosarcoma;   Adult Soft Tissue Sarcoma;   Childhood Alveolar Soft Part Sarcoma;   Childhood Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Childhood Hepatocellular Carcinoma;   Childhood Rhabdomyosarcoma;   Childhood Soft Tissue Sarcoma;   Childhood Solid Neoplasm;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adult Hepatocellular Carcinoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Hepatocellular Carcinoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Renal Cell Carcinoma;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Neuroendocrine Tumors;   Carcinoma, Small Cell Lung;   Carcinoma, Large Cell Lung;   Merkel Cell Carcinoma;   Pheochromocytoma;   Paraganglioma;   Thyroid Cancer, Medullary;   Neuroendocrine Carcinoma
    Intervention:   Drug: PEN-221
    Sponsor:   Tarveda Therapeutics
    Recruiting - verified May 2017

  • Condition:   Adrenal Gland Metastases
    Intervention:   Radiation: Stereotactic Body Radiation Therapy
    Sponsor:   Istituto Clinico Humanitas
    Recruiting - verified July 2016

  • Condition:   Anaphylactic Shock
    Intervention:   Other: skin ultrasound
    Sponsor:   Centre Hospitalier Régional Metz-Thionville
    Recruiting - verified July 2016

  • Conditions:   Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Dermoid Cyst;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Functional Pancreatic Neuroendocrine Tumor;   Malignant Somatostatinoma;   Merkel Cell Carcinoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B;   Neuroendocrine Neoplasm;   Non-Functional Pancreatic Neuroendocrine Tumor;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Merkel Cell Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Adrenal Cortex Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Thymic Carcinoid Tumor;   VIP-Producing Neuroendocrine Tumor;   Well Differentiated Adrenal Cortex Carcinoma;   Zollinger Ellison Syndrome
    Interventions:   Drug: Capecitabine;   Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified July 2016

  • Condition:   Adrenal Insufficiency
    Intervention:   Drug: Synachten
    Sponsor:   Haukeland University Hospital
    Recruiting - verified September 2016

  • Condition:   Cushing's Syndrome
    Intervention:   Drug: CORT125134
    Sponsor:   Corcept Therapeutics
    Recruiting - verified June 2017

  • Condition:   Post-ERCP Acute Pancreatitis
    Interventions:   Drug: epinephrine;   Drug: normal saline
    Sponsor:   Anhui Provincial Hospital
    Recruiting - verified July 2016

  • Condition:   Cushing Syndrome
    Intervention:  
    Sponsor:   Bnai Zion Medical Center
    Recruiting - verified October 2016

  • Condition:   Congenital Adrenal Hyperplasia
    Intervention:   Behavioral: Neuropsychological and cognitive assessment
    Sponsor:   Hospices Civils de Lyon
    Recruiting - verified February 2017

  • Conditions:   Adrenal Insufficiency;   Growth Disorder;   Endocrine Diseases;   Metabolic Disease;   Bone Diseases, Metabolic
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified April 14, 2017

  • Conditions:   Primary Aldosteronism;   Adrenal Adenoma
    Intervention:   Device: Radiofrequency ablation
    Sponsor:   University Hospital, Toulouse
    Not yet recruiting - verified August 2016

  • Condition:   Ectopic ACTH Syndrome
    Intervention:   Drug: Pasireotide
    Sponsors:   Cedars-Sinai Medical Center;   Novartis
    Recruiting - verified June 2017

  • Condition:   Acne Vulgaris
    Intervention:   Drug: cortexolone 17α-propionate
    Sponsor:   Cassiopea SpA
    Recruiting - verified February 2017

  • Conditions:   Hypotension;   Pain
    Interventions:   Drug: Ropivacaine;   Drug: Epinephrine
    Sponsors:   University of Florida;   I. Heermann Anesthesia Foundation
    Recruiting - verified February 2017

  • Condition:   Hyperaldosteronism
    Intervention:  
    Sponsor:   Haukeland University Hospital
    Recruiting - verified July 2016

  • Condition:   Malignant Neoplasms of Male Genital Organs
    Interventions:   Procedure: Caudal Nerve Block (CNB);   Drug: Ropivacaine;   Drug: Epinephrine;   Drug: Decadron;   Drug: Clonidine;   Drug: Propofol;   Behavioral: Phone Call
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified January 2017

  • Condition:   Adrenocortical Carcinoma
    Intervention:   Drug: Pembrolizumab
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Merck Sharp & Dohme Corp.
    Recruiting - verified May 2017

  • Conditions:   Adrenal Insufficiency;   Congenital Adrenal Hyperplasia;   Cushing Syndrome;   Growth Hormone Deficiency;   Acromegaly;   Primary Hyperaldosteronism
    Intervention:   Other: 27 hour subcutaneous fluid sampling
    Sponsors:   Haukeland University Hospital;   Karolinska Institutet;   University Hospitals Bristol NHS Foundation Trust;   Evaggelismos Hospital, Greece
    Not yet recruiting - verified October 2016

  • Condition:   Cushings Syndrome
    Intervention:   Other: Children refered to the obesity clinic
    Sponsor:   Haukeland University Hospital
    Recruiting - verified September 2016

  • Condition:   Diabetes Complications
    Interventions:   Drug: Epinephrine;   Other: Saline infusion
    Sponsors:   University of Maryland;   Vanderbilt University
    Recruiting - verified February 2017

  • Conditions:   Hypoxic-Ischemic Encephalopathy;   Asphyxia
    Interventions:   Drug: Hydrocortisone;   Drug: Placebo
    Sponsor:   Semmelweis University
    Recruiting - verified March 2017

  • Condition:   Primary Aldosteronism Due to Aldosterone Producing Adenoma
    Intervention:   Device: Renal Sympathetic Denervation
    Sponsor:   Henan Institute of Cardiovascular Epidemiology
    Recruiting - verified January 2017

  • Condition:   X-linked Adrenoleukodystrophy
    Intervention:   Dietary Supplement: vitamin D3
    Sponsors:   Stanford University;   National Institute of Neurological Disorders and Stroke (NINDS);   University of Minnesota - Clinical and Translational Science Institute;   ALD Connect, Inc.
    Recruiting - verified October 2016

  • Condition:   Plaque Psoriasis
    Intervention:   Drug: DSXS
    Sponsor:   Taro Pharmaceuticals USA
    Recruiting - verified May 2017

  • Conditions:   Osteoporosis;   Vitamin D Deficiency;   Cardiovascular Disease
    Interventions:   Drug: Valsartan;   Drug: Placebo Valsartan;   Dietary Supplement: Cholecalciferol;   Dietary Supplement: Placebo cholecalciferol
    Sponsor:   University of Aarhus
    Recruiting - verified May 2016

  • Condition:   Dermatitis, Atopic
    Intervention:   Drug: DSXS
    Sponsor:   Taro Pharmaceuticals USA
    Recruiting - verified May 2017

  • Conditions:   Children;   Bronchiolitis
    Interventions:   Drug: 0.9% saline solution;   Drug: oral betamethasone placebo;   Drug: adrenaline;   Drug: oral betamethasone
    Sponsors:   Assistance Publique - Hôpitaux de Paris;   Institut National de la Santé Et de la Recherche Médicale, France
    Recruiting - verified October 2016

  • Condition:   Cardiogenic Shock
    Intervention:   Drug: adrenaline
    Sponsors:   Niguarda Hospital;   Papa Giovanni XXIII Hospital
    Recruiting - verified March 2017

  • Conditions:   Stress;   Pituitary-Adrenal System
    Interventions:   Other: Contingent RT-fMRI-NF;   Other: Sham RT-fMRI-NF
    Sponsors:   University Hospital, Basel, Switzerland;   University of Basel;   Korea University
    Not yet recruiting - verified May 2017

  • Conditions:   Cushing's Syndrome;   Ectopic Corticotropin Syndrome;   Adrenal Adenoma;   Adrenal Carcinoma;   AIMAH;   PPNAD
    Intervention:   Drug: Osilodrostat
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified June 2017

  • Condition:   Adrenal Insufficiency
    Intervention:   Other: ACTH stimulation test
    Sponsors:   Radboud University;   AIDS Fonds;   OLVG
    Recruiting - verified October 2016

  • Conditions:   Anesthesia; Adverse Effect, Spinal and Epidural;   Hypotension;   Complications; Cesarean Section
    Interventions:   Drug: Norepinephrine;   Drug: Ephedrine
    Sponsor:   University Tunis El Manar
    Recruiting - verified August 2016

  • Condition:   Congenital Adrenal Hyperplasia
    Intervention:   Drug: Abiraterone acetate
    Sponsors:   University of Texas Southwestern Medical Center;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   University of Michigan;   Children's Hospital Los Angeles;   Feinstein Institute for Medical Research
    Not yet recruiting - verified September 2016

  • Conditions:   Thyroid Cancer, Medullary;   Carcinoid Tumor;   Pheochromocytoma;   Paraganglioma;   Insulinoma;   Neuroblastoma
    Intervention:   Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
    Sponsor:   British Columbia Cancer Agency
    Available - verified December 2016

  • Condition:   Cushing Syndrome
    Intervention:   Radiation: Adrenal venous sampling
    Sponsor:   Haukeland University Hospital
    Recruiting - verified September 2016

  • Condition:   Primary Aldosteronism
    Interventions:   Other: Adrenalectomy;   Drug: mineralocorticoid receptor antagonist
    Sponsors:   Vanderbilt University;   Brigham and Women's Hospital;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting - verified August 2016

  • Conditions:   Adrenal Incidentaloma;   Adrenocortical Carcinoma
    Intervention:  
    Sponsors:   University Medical Center Groningen;   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   VU University Medical Center;   Radboud University;   Leiden University Medical Center;   Maastricht University Medical Center;   UMC Utrecht;   Erasmus Medical Center;   Martini Hospital Groningen;   Canisius-Wilhelmina Hospital;   Diakonessenhuis, Utrecht;   Isala;   Haga Hospital;   St. Antonius Hospital;   Kennemer Gasthuis;   Maxima Medical Center;   Medical Center Alkmaar;   Medical Centre Leeuwarden;   Meander Medical Center;   Medisch Spectrum Twente;   Onze Lieve Vrouwe Gasthuis;   Rijnstate Hospital;   Elisabeth-TweeSteden Ziekenhuis;   Tergooi Hospital;   Vlietland Ziekenhuis;   Scheper Hospital;   Flevo Hospital
    Recruiting - verified June 2017

  • Condition:   Plaque Psoriasis
    Intervention:   Drug: Topicort® (desoximetasone) Topical Spray, 0.25%
    Sponsor:   Taro Pharmaceuticals USA
    Recruiting - verified May 2017

  • Condition:   Cushing's Syndrome
    Intervention:   Drug: metyrapone
    Sponsor:   HRA Pharma
    Recruiting - verified February 2017

  • Conditions:   Adrenoleukodystrophy;   Batten Disease;   Mucopolysaccharidosis II;   Leukodystrophy, Globoid Cell;   Leukodystrophy, Metachromatic;   Neimann Pick Disease;   Pelizaeus-Merzbacher Disease;   Sandhoff Disease;   Tay-Sachs Disease;   Brain Diseases, Metabolic, Inborn
    Intervention:   Biological: DUOC-01
    Sponsors:   Joanne Kurtzberg, MD;   The Marcus Foundation
    Recruiting - verified April 2017

  • Conditions:   Endocrine System Disease;   Cardiovascular Imaging
    Interventions:   Other: 1H magnetic resonance spectroscopy and CMRI;   Other: 1H magnetic resonance spectroscopy and CMRI
    Sponsor:   Assistance Publique - Hôpitaux de Paris
    Recruiting - verified September 2016

  • Conditions:   X-Linked Adrenoleukodystrophy (X-ALD);   Cerebral Adrenoleukodystrophy (CALD);   Adrenoleukodystrophy (ALD)
    Intervention:   Genetic: Allo-HSCT
    Sponsor:   bluebird bio
    Recruiting - verified May 2017

  • Conditions:   Liver Cancer;   Lung Cancer
    Interventions:   Drug: Ipilimumab;   Radiation: Stereotactic Body Radiation Therapy (SBRT)
    Sponsors:   M.D. Anderson Cancer Center;   Bristol-Myers Squibb
    Recruiting - verified June 2017

  • Conditions:   Mucopolysaccharidosis Disorders;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux Lamy Syndrome;   Sly Syndrome;   Alpha-Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Glycoprotein Metabolic Disorders;   Sphingolipidoses;   Recessive Leukodystrophies;   Globoid Cell Leukodystrophy;   Metachromatic Leukodystrophy;   Niemann-Pick B;   Niemann-Pick C Subtype 2;   Sphingomyelin Deficiency;   Peroxisomal Disorders;   Adrenoleukodystrophy With Cerebral Involvement;   Zellweger Syndrome;   Neonatal Adrenoleukodystrophy;   Infantile Refsum Disease;   Acyl-CoA Oxidase Deficiency;   D-Bifunctional Enzyme Deficiency;   Multifunctional Enzyme Deficiency;   Alpha-methylacyl-CoA Racmase Deficiency;   Mitochondrial Neurogastrointestingal Encephalopathy;   Severe Osteopetrosis;   Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation);   Inherited Metabolic Disorders
    Interventions:   Biological: Stem Cell Transplantation;   Drug: IMD Preparative Regimen;   Drug: Osteopetrosis Only Preparative Regimen;   Drug: Osteopetrosis Haploidentical Only Preparative Regimen;   Drug: cALD SR-A (Standard-Risk, Regimen A);   Drug: cALD SR-B (Standard-Risk, Regimen B);   Drug: cALD HR-D (High-Risk, Regimen C);   Drug: cALD HR-D (High-Risk, Regimen D)
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified June 2017

  • Condition:   X-linked Adrenoleukodystrophy
    Intervention:   Drug: Lorenzo's Oil
    Sponsor:   University of Minnesota - Clinical and Translational Science Institute
    Available - verified December 2016

  • Condition:   Cushing Syndrome
    Interventions:   Drug: F-DOPA PET Scan;   Drug: Mifepristone;   Drug: Ga-DOTATATE;   Drug: Octreoscan;   Other: CT, MRI
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified February 22, 2017

  • Conditions:   Addison Disease;   Adrenal Hyperplasia Congenital
    Interventions:   Drug: Solu-Cortef;   Drug: Cortef
    Sponsor:   Haukeland University Hospital
    Recruiting - verified December 2016

  • Conditions:   Pheochromocytoma;   Adrenal Incidentaloma
    Intervention:   Procedure: Removal of adrenal tumor
    Sponsor:   University of Aarhus
    Recruiting - verified October 2016

  • Conditions:   Adrenocortical Carcinoma;   Adrenal Cancer;   ACC
    Intervention:   Drug: ATR-101
    Sponsor:   Millendo Therapeutics, Inc.
    Recruiting - verified February 2017

  • Condition:   Endogenous Cushing's Syndrome
    Intervention:   Drug: COR-003
    Sponsor:   Cortendo AB
    Recruiting - verified June 2017

  • Condition:   Cerebral Adrenoleukodystrophy (CALD)
    Intervention:   Genetic: Lenti-D Drug Product
    Sponsor:   bluebird bio
    Recruiting - verified June 2017

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group;   Mucolipidosis Type IV Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated
    Recruiting - verified September 2016

  • Condition:   Adrenal Hyperplasia, Congenital
    Interventions:   Drug: Hydrocortisone;   Drug: Cortisone acetate
    Sponsor:   Haukeland University Hospital
    Recruiting - verified December 2016

  • Condition:   Long QT Syndrome Type 1 or 2
    Interventions:   Other: exercise test;   Other: Epinephrine test
    Sponsor:   Nantes University Hospital
    Recruiting - verified October 2016

  • Condition:   Asthma
    Interventions:   Drug: IM epinephrine 1:1000;   Other: No intervention
    Sponsor:   University of Louisville
    Recruiting - verified March 2017

  • Condition:   Chronic Adrenal Insufficiency
    Intervention:  
    Sponsor:   Shire
    Recruiting - verified January 2017

  • Conditions:   Mucopolysaccharidosis I;   Mucopolysaccharidosis VI;   Adrenoleukodystrophy;   Niemann-Pick Disease;   Metachromatic Leukodystrophy;   Wolman Disease;   Krabbe's Disease;   Gaucher's Disease;   Fucosidosis;   Batten Disease;   Severe Aplastic Anemia;   Diamond-Blackfan Anemia;   Amegakaryocytic Thrombocytopenia;   Myelodysplastic Syndrome;   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia
    Intervention:   Drug: Human Placental Derived Stem Cell
    Sponsor:   New York Medical College
    Recruiting - verified July 2016

  • Conditions:   Cushing's Syndrome;   Adrenal Incidentalomas;   Alcoholism;   Obesity
    Intervention:  
    Sponsor:   Haukeland University Hospital
    Recruiting - verified September 2016

  • Conditions:   Adenovirus;   Adrenal Insufficiency;   Airway Swelling;   Anesthesia;   Anxiety;   Anxiolysis;   Autism;   Autistic Disorder;   Bacterial Meningitis;   Bacterial Septicemia;   Benzodiazepine;   Bipolar Disorder;   Bone and Joint Infections;   Brain Swelling;   Central Nervous System Infections;   Convulsions;   Cytomegalovirus Retinitis;   Early-onset Schizophrenia Spectrum Disorders;   Edema;   Epilepsy;   General Anesthesia;   Gynecologic Infections;   Headaches;   Herpes Simplex Virus;   Hypertension;   Infantile Hemangioma;   Infection;   Inflammation;   Inflammatory Conditions;   Influenza;   Intra-abdominal Infections;   Lower Respiratory Tract Infections;   Migraines;   Pain;   Pneumonia;   Prophylaxis;   Schizophrenia;   Sedation;   Seizures;   Skeletal Muscle Spasms;   Skin and Skin-structure Infections;   Stable Angina;   Thromboprophylaxis;   Thrombosis;   Treatment-resistant Schizophrenia;   Urinary Tract Infection;   Withdrawal
    Intervention:   Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
    Sponsors:   Daniel Benjamin;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   The EMMES Corporation;   OpAns, LLC
    Recruiting - verified March 2017

  • Condition:   Rheumatoid Arthritis
    Intervention:   Diagnostic Test: Synacthen test
    Sponsor:   Rigshospitalet, Denmark
    Recruiting - verified April 2017

  • Conditions:   Obesity;   Hyperandrogenemia;   Polycystic Ovary Syndrome
    Intervention:   Drug: Metformin
    Sponsor:   University of Virginia
    Recruiting - verified December 2016

  • Conditions:   Obesity;   Hyperandrogenemia;   Polycystic Ovary Syndrome
    Intervention:   Drug: Spironolactone
    Sponsor:   University of Virginia
    Recruiting - verified December 2016

  • Conditions:   Hyperandrogenemia;   Obesity;   Polycystic Ovary Syndrome
    Interventions:   Drug: Hydrocortisone;   Drug: dexamethasone;   Drug: Cosyntropin;   Drug: rhCG
    Sponsor:   University of Virginia
    Not yet recruiting - verified December 2016

  • Conditions:   Hyperandrogenemia;   Obesity;   Polycystic Ovary Syndrome
    Intervention:   Drug: Hydrocortisone
    Sponsor:   University of Virginia
    Not yet recruiting - verified December 2016

  • Condition:   Adrenal Gland Neoplasms
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 28, 2016

  • Condition:   Adrenal Tumour With Mild Hypercortisolism
    Intervention:   Procedure: Adrenalectomy
    Sponsor:   Region Skane
    Recruiting - verified April 2017

  • Conditions:   Endocrine Neoplasms;   Thyroid Neoplasms;   Parathyroid Neoplasms;   Adrenal Neoplasm;   Neuroblastoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2, 2016

  • Condition:   Adrenocortical Carcinoma
    Intervention:   Drug: MITOTANE
    Sponsor:   University of Turin, Italy
    Recruiting - verified May 2017

  • Condition:   Adrenocortical Tumor
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified November 2016

  • Conditions:   Adrenal Tumors;   Adrenocortical Carcinoma;   Cushing Syndrome;   Conn Syndrome;   Pheochromocytoma
    Intervention:  
    Sponsors:   University of Wuerzburg;   Deutsche Krebshilfe e.V., Bonn (Germany);   German Federal Ministry of Education and Research
    Recruiting - verified October 2016

  • Condition:   Adrenocortical Carcinoma
    Intervention:  
    Sponsor:   University of Wuerzburg
    Recruiting - verified October 2016

  • Condition:   Adrenocortical Carcinoma
    Intervention:  
    Sponsors:   University of Wuerzburg;   Deutsche Krebshilfe e.V., Bonn (Germany)
    Recruiting - verified October 2016

  • Condition:   Adrenal Gland Neoplasm
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified March 24, 2017

  • Conditions:   Adrenal Insufficiency;   Pituitary Neoplasm;   Obesity
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified April 6, 2017

  • Condition:   Pheochromocytoma
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified May 30, 2017

  • Conditions:   Cushing's Syndrome;   Hereditary Neoplastic Syndrome;   Lentigo;   Neoplasm;   Testicular Neoplasm
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified March 2, 2017

  • Conditions:   Abnormalities;   Craniopharyngioma;   Cushing's Syndrome;   Endocrine Disease;   Pituitary Neoplasm
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified June 8, 2017

  • Condition:   Cushing Syndrome
    Interventions:   Drug: Pentetreotide;   Drug: 18-F-fluorodeoxyglucose;   Drug: (18F)-L-3,4-dihydroxyophenylalanine (18F-DOPA)
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified May 3, 2017

  • Conditions:   XXY (Klinefelter);   Sex Chromosome Variation;   Sex Chromosome Aneuploidy;   XXXY;   XXXXXY;   XYY (Jacob);   XXYY;   X (XO, Turner);   XXX (Trisomy X, Triple X);   XXXX (Tetrasomy X);   XXXXX (Pentasomy X)
    Intervention:  
    Sponsor:   National Institute of Mental Health (NIMH)
    Recruiting - verified March 29, 2017